Learn More
Despite internal complexity, tumor growth kinetics follow relatively simple laws that can be expressed as mathematical models. To explore this further, quantitative analysis of the most classical of these were performed. The models were assessed against data from two in vivo experimental systems: an ectopic syngeneic tumor (Lewis lung carcinoma) and an(More)
Mathematical analysis of a two-dimensional population model of metastatic growth including angiogenesis. Abstract Angiogenesis is a key process in the tumoral growth which allows the cancerous tissue to impact on its vasculature in order to improve the nutrient's supply and the metastatic process. In this paper, we introduce a model for the density of(More)
Autopsy studies of adults dying of non-cancer causes have shown that virtually all of us possess occult, cancerous lesions. This suggests that, for most individuals, cancer will become dormant and not progress, while only in some will it become symptomatic disease. Meanwhile, it was recently shown in animal models that a tumor can produce both stimulators(More)
Although optimal control theory has been used for the theoretical study of anti-cancerous drugs scheduling optimization, with the aim of reducing the primary tumor volume, the effect on metastases is often ignored. Here, we use a previously published model for metastatic development to define an optimal control problem at the scale of the entire organism of(More)
Rapid improvements in the detection and tracking of early-stage tumor progression aim to guide decisions regarding cancer treatments as well as predict metastatic recurrence in patients following surgery. Mathematical models may have the potential to further assist in estimating metastatic risk, particularly when paired with in vivo tumor data that(More)
Oncology has benefited from an increasingly growing number of groundbreaking innovations over the last decade. Targeted therapies, biotherapies, and the most recent immunotherapies all contribute to increase the number of therapeutic options for cancer patients. Consequently, substantial improvements in clinical outcomes for some disease with dismal(More)
Aging is the major determinant of cancer incidence, which, in turn, is likely dictated in large part by processes that influence the progression of early subclinical (occult) cancers. However, there is little understanding of how aging informs changes in aggregate host signaling that favor cancer progression. In this study, we provide direct evidence that(More)
We prove the convergence of a family of solutions to a two-dimensional transport equation with a non-local boundary condition modelling the evolution of a population of metastases. We show that when the data of the repartition along the boundary tend to a Dirac mass, then the solution of the associated problem converges and we derive a simple expression for(More)
Combining radiotherapy with immune checkpoint blockade may offer considerable therapeutic impact if the immunosuppressive nature of the tumor microenvironment (TME) can be relieved. In this study, we used mathematical models, which can illustrate the potential synergism between immune checkpoint inhibitors and radiotherapy. A discrete-time pharmacodynamic(More)
In their interesting paper published recently in PNAS (1), Heist et al. report the clinical benefits of combining antiangiogenic bevacizumab, with the doublet carboplatin plus nab-paclitaxel, in non-small cell lung cancer (NSCLC) patients. This regimen demonstrated promising efficacy. Interestingly, whereas functional imaging showed that bevacizumab exerts(More)